CERO THERAPEUTICS HOLDINGS, INC. (CERO)
CERo Therapeutics Holdings, Inc. is a biotech firm dedicated to pioneering advanced engineered T-cell immunotherapies for the treatment of various cancers. Their leading therapeutic candidate, CER-1236, is an autologous T-cell therapy currently in development, aimed at addressing both blood cancers (hematologic malignancies) and solid tumors. This company was founded in 2021 and is headquartered in South San Francisco, California.
Sector: Biological Products, (No Diagnostic Substances)
Industry: Biotechnology
CERo Therapeutics Holdings, Inc.
OTC:CEROHealthcare · Biotechnology
-4.17%$0.0046
Prev close$0.0048-16.67%Open$0.0040+15.00%Now$0.0046
Mkt Cap$383K
EV-
Float–
O/S83.31M
VOL105K sh
$ Vol$463
RVOL0.28×
Inst Own-
Net Cash/Sh-
EarningsDec 2 · in 2w
Dilution
MCap$383KFloat–O/S83.31M
Dilution
| Form | Description | Links | |
|---|---|---|---|
| 10-Q | |||
| 8-K | |||
| 8-K | |||
| 424B3 | |||
| 10-Q | |||
| 13G/A | |||
| 424B3 | |||
| 8-K | |||
| 25-NSE | |||
| 424B3 | |||
| 8-K | |||
| 424B3 | |||
| 8-K | |||
| 424B3 | |||
| 10-Q | |||
| 424B3 | |||
| 8-K | |||
| 424B3 | |||
| 10-K/A | |||
| 4 | |||
| 3 | |||
| 424B3 | |||
| 10-K | |||
| 424B3 | |||
| 8-K |
1-25 of 446 filings
…
Recent SEC filings with analysis
- 10-QCERo Therapeutics Holdings reported a going-concern warning in its Q3 2026 10-Q, holding just $650,681 in cash against a working capital deficit of…
- 8-KCERo Therapeutics Holdings signed a Stock Purchase Agreement on October 6, 2026 to sell 100% of its operating subsidiary, CERo Therapeutics, Inc., to SRX…